Liberty Health Sciences Opens Dispensary in Heart of Miami on Bird Road

• Eighth dispensary to open providing physical location for Southern Florida
• Three additional dispensaries opening in December

TORONTO, Dec. 11, 2018 /CNW/ - Liberty Health Sciences Inc. LHS LHSIF www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced that the Company has opened its first south Florida dispensary today in the heart of Miami. The new dispensary provides customers in Miami-Dade County, the most populous county in Florida, access to premium quality medical marijuana products and educational services.  

Located at 6827 Bird Road, Miami, FL., the state-of-the art dispensary is open Monday through Friday, 10 a.m. to 7p.m., Saturday, 10 a.m. to 5 p.m., and Sunday 12 p.m. to 5 p.m. Bird Road is one of the oldest and busiest state roads in Miami, with traffic exceeding 70,000 vehicles per day. It is a primary artery that feeds the main suburbs in Miami such as Coral Gables, West Miami, South Miami, Westchester, and Kendall. In addition to the Miami location, Liberty plans to open 3 more dispensaries this month with more to come in 2019, all subject to the receipt of Florida Department of Health approvals.     

"Liberty remains committed to ensuring that its premium quality medical marijuana products and educational services are accessible to the more than 2.7 million people who call South Florida home," said George Scorsis, CEO of Liberty Health Sciences. "When people come to our dispensaries, they know they will find the highest quality medicinal cannabis. They also trust that they are going to have access to the best brands in any category, including PAX and Mary's Medicinals products.

"No other company has a brand-house and selection like ours. This demonstrates that not only do our partner brands trust and believe in us to deliver against their goals and objectives, but that consumers also have a diverse selection of the best products available," said George Scorsis, CEO of Liberty Health Sciences.

In order to keep up with the growing footprint of dispensaries and patient demand, Liberty is expanding the Company's production capacity of the Liberty 360 facility in Gainesville, Florida, expected to be completed in stages in 2019. The Liberty 360 operation currently has 20,000 square feet of cultivation space on-line at the facility and the next phase of 80,000 square feet is expected to be completed by February 2019. The Company has also greatly expanded its R&D capabilities at the Liberty 360 facility in terms of delivery systems and continues to develop different formats of cannabis.

About Liberty Health Sciences Inc.
Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty's measured approach to expansion opportunities maximizes returns to shareholders, while keeping consumers' well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com.       

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company's production capabilities, expectations concerning the receipt of all necessary approvals from the Florida Department of Health, expectations concerning the opening of new dispensaries and the expansion of its greenhouse space, and the Company's future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Liberty Health Sciences Inc.

View original content: http://www.newswire.ca/en/releases/archive/December2018/11/c7788.html